|
Imaging Biometrics Ltd on Friday reported positive study results for IB Neuro, and detailed its commercialisation strategy for the platform. In response, shares in Imaging Biometrics surged 57% higher to trade at 0.94 pence on Friday afternoon in London. The medical imaging technology company presented the results from the EAF151 phase 2 clinical trial, conducted across 33 centres and 146 patients, on May 31 at the American Society of Clinical Oncology’s Annual Meeting. The study was evaluating dynamic susceptibility contrast MRI-derived cerebral blood volume, computed using IB Neuro, as a potential early and objective biomarker of response to bevacizumab in recurrent glioblastoma. Imaging Biometrics said IB Neuro was used on normalised and standardised relative cerebral blood volume, with mean values calculated within the dT1-defined contrast-enhancing regions. The company said that rCBV measurements, both baseline and two weeks post-treatment, demonstrated meaningful associations with patient outcomes. ‘Notably, IB Neuro’s sRCBV, a fully automated and operator-independent output map, unique to IB, showed the strongest statistically significant association with overall survival (OS), outperforming manually normalised rCBV,’ Imaging Biometrics said. It said that bevacizumab, a targeted cancer drug which targets the vascular endothelial growth factor cancer cell protein, is costly and does not benefit all patients. Consequently, it believes that an objective early-response signal has material clinical and economic value. ‘The EAF151 results show that the technology built in IB Neuro can provide early, objective signals of treatment response - within weeks rather than months - offering the potential to streamline clinical trials and help clinicians everywhere identify more effective treatment strategies sooner,’ commented Michael Schmainda, the chief executive officer of US operating subsidiary Imaging Biometrics LLC. Imaging Biometrics said its commercialisation strategy for the platform will target participating EAF151 sites, and organisations conducting clinical trials with anti-angiogenic agents, through direct sales channels and global distribution partners. ‘The EAF151 results provide prospective clinical validation of this approach, positioning IB Neuro’s sRCBV as an operationally practical and readily deployable solution in comparable trial settings and for routine clinical use,’ the company explained. ‘Collectively, these opportunities underpin a capital-efficient strategy focused on generating incremental revenue from existing infrastructure without the need for material external funding.’ Copyright 2026 Alliance News Ltd. All Rights Reserved.
|
